Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center

Bergman, Philip J.; Camps‐Palau, Maria A.; McKnight, J. A.; Leibman, Nicole F.; Craft, D. M.; Leung, C.; Liao, J.; Rivière, Isabelle; Sadelain, Michel; Hohenhaus, Ann E.; Gregor, Polly D.; Houghton, Alan N.; Perales, Miguel-Ángel; Wolchok, Jedd D.

doi:10.1016/j.vaccine.2005.08.027

Cited by 252 publications

(192 citation statements)

References 21 publications

Supporting

Mentioning

171

Contrasting

Unclassified

Order By: Relevance

“…Pigs. Pigs were confirmed negative for influenza-reactive Abs (,2 3 ) in an HI assay, and DNA (pUMVC-vector) was immunized either by i.d. needle injection followed by skin electroporation (Agile Pulse; Harvard Apparatus/BTX) or by i.d.…”

Section: Vaccination and Viral Challengementioning

confidence: 99%

Antigen Targeting to Human HLA Class II Molecules Increases Efficacy of DNA Vaccination

Grødeland

Fredriksen²,

Løset

et al. 2016

The Journal of Immunology

View full text Add to dashboard Cite

It has been difficult to translate promising results from DNA vaccination in mice to larger animals and humans. Previously, DNA vaccines encoding proteins that target Ag to MHC class II (MHC-II) molecules on APCs have been shown to induce rapid, enhanced, and long-lasting Ag-specific Ab titers in mice. In this study, we describe two novel DNA vaccines that as proteins target HLA class II (HLA-II) molecules. These vaccine proteins cross-react with MHC-II molecules in several species of larger mammals. When tested in ferrets and pigs, a single DNA delivery with low doses of the HLA-II–targeted vaccines resulted in rapid and increased Ab responses. Importantly, painless intradermal jet delivery of DNA was as effective as delivery by needle injection followed by electroporation. As an indication that the vaccines could also be useful for human application, HLA-II–targeted vaccine proteins were found to increase human CD4+ T cell responses by a factor of ×103 in vitro. Thus, targeting of Ag to MHC-II molecules may represent an attractive strategy for increasing efficacy of DNA vaccines in larger animals and humans.

show abstract

Section: Vaccination and Viral Challengementioning

confidence: 99%

Antigen Targeting to Human HLA Class II Molecules Increases Efficacy of DNA Vaccination

Grødeland

Fredriksen²,

Løset

et al. 2016

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…31 Plasmids were purified from bacterial lysates using Qiagen columns (Qiagen, Valencia, CA), and DNA was precipitated on gold, coated on plastic tubing and injected in the skin of mice, as described previously. 26,37 Fusion of splenocytes An immunized mouse was rested for several months, boosted once with PSMA protein eluted from anti-mouse-agarose beads and 3 days later splenocytes were fused to the myeloma Sp2/0-Ag14 using a polyethyleneglycol-based fusion protocol modified by the Monoclonal Antibody Core Facility at MSKCC.…”

Section: Immunizationmentioning

confidence: 99%

“…[27][28][29][30] Outbred dogs with spontaneous melanoma immunized with xenogeneic tyrosinase DNA vaccines showed prolonged survival compared to historical controls. 31 Preclinical studies in rats led to a clinical trial in which some patients immunized with rat prostatic acid phosphatase (PAP) responded to both rat and human PAP proteins. 32 Using this paradigm, we have immunized mice with xenogeneic human PSMA (hPSMA), which shares 85% identity with mouse PSMA (mPSMA) at the amino acid level and has a similar tissue distribution.…”

mentioning

confidence: 99%

Induction of autoantibodies to syngeneic prostate‐specific membrane antigen by xenogeneic vaccination

Gregor

Wolchok

Turaga

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

Prostate-specific membrane antigen (PSMA) is a prototypical differentiation antigen expressed on normal and neoplastic prostate epithelial cells, and on the neovasculature of many solid tumors. Monoclonal antibodies specific for PSMA are in development as therapeutic agents. Methodologies to actively immunize against PSMA may be limited by immunologic ignorance and/or tolerance that restrict the response to self-antigens. Our studies have previously shown that xenogeneic immunization with DNA vaccines encoding melanosomal differentiation antigens induces immunity in a mouse melanoma model. Here we apply this approach to PSMA to establish proof of principle in a mouse model. Immunization with xenogeneic human PSMA protein or DNA induced antibodies to both human and mouse PSMA in mice. Monoclonal antibodies specific for mouse PSMA were generated to analyze antibody isotypes and specificity for native and denatured PSMA at the clonal level. Most antibodies recognized denatured PSMA, but C57BL/6 mice immunized with xenogeneic PSMA DNA followed by a final boost with xenogeneic PSMA protein yielded autoantibodies that reacted with native folded mouse PSMA. Monoclonal antibodies were used to confirm the expression of PSMA protein in normal mouse kidney. These results establish the basis for clinical trials to test PSMA DNA vaccines in patients with solid tumors that either express PSMA directly or that depend on normal endothelial cells expressing PSMA for their continued growth. ' 2005 Wiley-Liss, Inc.

show abstract

“…Using recombinant deoxyribonucleic acid (rDNA) technologies, these vaccines no longer cause disease, but still induce a strong immune response. Paralleling the development of new, more efficacious, stable, and safe recombinant vaccines has been the study of vaccine delivery methods and immunostimulating adjuvant compounds that enhance the immune response (Bergman et al,2006). Advances in gene discovery of animal pathogens can be expected to identify new proteins and metabolic pathways, thereby providing a foundation for improved understanding of pathogen biology and, ultimately, aiding in the design of new and effective therapies.…”

Section: Vaccine Development Using Recombinant Dna Technologymentioning

confidence: 99%

Review on current application of genomic biotechnologies to improve livestock and livestock products

2017

Int. J. Adv. Res. Biol. Sci

View full text Add to dashboard Cite

An organism's genome is the 'blueprint of life,' the complete set of instructions for making the molecules, cells and tissues that control how an animal can perform throughout its life. Every cell in the body contains the complete genome, encoded in the form of DNA. This review was conducted to give emphasis about the role or the current application of some advance genomic biotechnologies in animal breeding, disease diagnosis and prevention and control strategies. There are opportunities for using molecular genetics to identify genes that are involved in variety of traits. Revolutionary opportunities for the modification of animal performance are being created by the development of new methods (reproductive technology) for embryo manipulation and the application of molecular biology (cloning and transgenesis). Consequently, new approaches are needed to develop improved tools and strategies for prevention and control of infectious diseases in animal agriculture. Among the most effective and successful of these tools are animal vaccines using recombinant deoxyribonucleic acid (rDNA) technologies. In the recent years a profound change has occurred with the introduction of new genomic biotechnological assays for the diagnosis of infectious diseases of livestock and zoonotic pathogens. These new assays include various forms of PCR, genomic sequencing, DNA probes and DNA microarray technology, Nanotechnology, Restriction fragment length polymorphisms and Pulsed field gel electrophoresis. Generally animal genomics is of interest because of its importance to produce high quality food products economically and efficiently to furnish for the increasing supply demand gap all over the world.

show abstract

Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center

Cited by 252 publications

References 21 publications

Antigen Targeting to Human HLA Class II Molecules Increases Efficacy of DNA Vaccination

Antigen Targeting to Human HLA Class II Molecules Increases Efficacy of DNA Vaccination

Induction of autoantibodies to syngeneic prostate‐specific membrane antigen by xenogeneic vaccination

Review on current application of genomic biotechnologies to improve livestock and livestock products

Contact Info

Product

Resources

About